Security Snapshot

Avadel Pharmaceuticals plc - American Depositary Shares, each representing one Ordinary Share, nominal value $0.01 per share (AVDL) Institutional Ownership

CUSIP: 05337M104

13F Institutional Holders and Ownership History from Q4 2016 to Q4 2025

Latest Period

Q4 2025

Institutions Reporting

2

Shares (Excl. Options)

600,001

Price

$18.78

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.

Create free account to save this page Review latest holder period
Type / Class
Equity / American Depositary Shares, each representing one Ordinary Share, nominal value $0.01 per share
Symbol
AVDL on Nasdaq
Shares outstanding
98,762,388
Price per share
$18.78
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
600,001
Total reported value
$12,930,016
Share change
-137,500
Value change
-$2,099,625
Number of holders
2
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Quick Takeaways

  • AVDL - Avadel Pharmaceuticals plc - American Depositary Shares, each representing one Ordinary Share, nominal value $0.01 per share is tracked under CUSIP 05337M104.
  • 2 institutions reported positions in Q4 2025.
  • 1 significant owner is listed from Schedule 13D/13G reporting.

What Changed

  • Holder count moved from 3 to 2 between Q3 2025 and Q4 2025.
  • Reported value moved from $11,261,641 to $12,930,016.

Why This Matters

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Source Evidence

Source: SEC Form 13F

Latest holder context comes from 2 institutions filings for Q4 2025.

Open SEC Evidence

Investment Quick Answers

What is CUSIP 05337M104?
CUSIP 05337M104 identifies AVDL - Avadel Pharmaceuticals plc - American Depositary Shares, each representing one Ordinary Share, nominal value $0.01 per share in SEC 13F datasets.

Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.

Significant Owners of Avadel Pharmaceuticals plc - American Depositary Shares, each representing one Ordinary Share, nominal value $0.01 per share (AVDL) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
GENDELL JEFFREY L 4.9% 4,839,357 Jeffrey L. Gendell 31 Dec 2025

As of 31 Dec 2025, 2 institutional investors reported holding 600,001 shares of Avadel Pharmaceuticals plc - American Depositary Shares, each representing one Ordinary Share, nominal value $0.01 per share (AVDL). This represents 0.61% of the company’s total 98,762,388 outstanding shares.

Institutional Holders of Avadel Pharmaceuticals plc - American Depositary Shares, each representing one Ordinary Share, nominal value $0.01 per share (AVDL) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 600,001 $12,930,016 -$2,099,625 $18.78 2
2025 Q3 737,501 $11,261,641 $15.27 3
2025 Q2 737,501 $6,526,891 $8.85 3
2025 Q1 737,501 $5,774,641 +$3,915 $7.83 3
2024 Q4 737,001 $7,745,886 -$4,367,115 $10.51 3
2024 Q3 1,070,001 $14,032,886 -$83,726,145 $13.12 5
2024 Q2 7,025,014 $98,771,327 -$1,024,949,936 $14.06 10
2024 Q1 67,722,532 $1,143,898,167 +$203,068,084 $16.89 118
2023 Q4 56,101,941 $792,157,961 +$22,530,113 $14.12 111
2023 Q3 54,278,206 $559,092,743 +$10,494,218 $10.30 97
2023 Q2 51,954,100 $856,215,990 +$74,681,603 $16.48 100
2023 Q1 48,372,275 $443,043,185 +$137,759,207 $9.16 89
2022 Q4 33,455,552 $239,492,674 +$16,050,496 $7.16 83
2022 Q3 31,382,476 $157,240,505 -$10,626,389 $5.01 73
2022 Q2 33,736,494 $82,314,348 -$28,513,599 $2.44 76
2022 Q1 35,805,994 $244,546,225 -$688,773 $6.83 78
2021 Q4 34,932,136 $282,263,295 +$4,296,837 $8.08 80
2021 Q3 32,066,701 $314,225,653 -$2,362,887 $9.80 81
2021 Q2 32,560,006 $219,142,519 -$1,408,221 $6.73 78
2021 Q1 32,624,275 $294,399,454 +$1,571,028 $9.04 77
2020 Q4 32,022,142 $213,943,727 +$3,675,725 $6.68 79
2020 Q3 31,489,522 $158,737,955 -$40,676,485 $5.04 77
2020 Q2 36,267,175 $293,031,072 +$73,438,051 $8.08 73
2020 Q1 26,858,841 $211,297,159 +$55,745,053 $7.94 55
2019 Q4 18,381,676 $138,778,000 +$3,405,718 $7.55 42
2019 Q3 19,369,854 $80,579,000 +$264,036 $4.16 40
2019 Q2 19,348,881 $55,916,464 -$532,703 $2.89 41
2019 Q1 19,605,364 $28,234,677 -$885,274 $1.44 39
2018 Q4 19,797,043 $51,037,773 -$3,326,792 $2.58 49
2018 Q3 20,161,887 $88,500,210 -$2,841,826 $4.39 63
2018 Q2 20,601,522 $126,287,755 -$36,188,917 $6.13 67
2018 Q1 25,894,045 $188,761,103 -$4,895,064 $7.29 72
2017 Q4 26,385,773 $216,351,759 -$17,017,220 $8.20 76
2017 Q3 27,182,084 $284,631,551 -$5,504,957 $10.50 79
2017 Q2 27,736,858 $305,936,220 +$24,728,608 $11.03 76
2017 Q1 27,900,060 $270,237,807 +$228,176,242 $9.68 70
2016 Q4 4,300,449 $44,678,000 +$44,678,000 $10.39 6
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .